Novo Nordisk Growth Projections: Insights on 2025 Performance and 2026 Outlook

Novo Nordisk’s company announcement details 2025 financial results and a 2026 outlook, with Novo Nordisk growth projections highlighting 10% sales growth and 6% operating profit growth at constant exchange rates (CER) for 2025, matching prior guidance. It introduces non-IFRS adjusted measures for 2026, excluding items like a USD 4.2 billion reversal of sales rebate provisions from the US 340B Drug Pricing Program, forecasting adjusted sales and operating profit decline of -5% to -13% at CER. Non-adjusted midpoints show -1% sales growth and 11% operating profit growth, capturing core business trends amid expansions and pricing headwinds.

Regional Sales Pressures Fuel Decline

Novo Nordisk decline projections for adjusted sales (-5% to -13% at CER) reflect uneven regional results and external factors. US operations face declines from rising competition, shrinking obesity drug Medicaid coverage, Most Favored Nations (MFN) pricing impacts, and absent 2025 gross-to-net adjustments. International markets expect gains from GLP-1 volume growth in obesity care, Wegovy expansions including a 7.2mg dose, offset by semaglutide patent losses and rivals. Quarterly swings and currency effects loom, with Danish krone figures trailing CER by 3 points due to USD weakening.

HEOR Challenges in Pricing Shifts

These Novo Nordisk decline projections test GLP-1 value amid MFN and 340B changes that alter obesity/diabetes cost models. US price cuts and Medicaid curbs complicate payer talks, demanding strong HEOR data versus competition and semaglutide biosimilars abroad. Amid volume-focused trends—Wegovy pills, self-pay options—Novo Nordisk eyes pipeline wins, urging payers to weigh affordability against chronic care innovations.